Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 12/20 | 0.74 |
| ▸ | CDC25B | P30305 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18813442 | 0.98 | HCAR3 (0.72) | HCAR3CDC25BHTTALDH1A1MAPT | |
| SCHEMBL321911 | 0.85 | HCAR3 (1.00) | HCAR3CDC25BMEN1KMT2A | |
| SCHEMBL973813 | 0.85 | HCAR3 (0.77) | HCAR3CDC25BHTTALDH1A1MAPT | |
| SCHEMBL3620745 | 0.84 | KMT2A (0.65) | HCAR3HTTALDH1A1MAPTMEN1 | |
| SCHEMBL2253159 | 0.84 | HCAR3 (0.74) | HCAR3CDC25BHTTALDH1A1MAPT | |
| SCHEMBL10665446 | 0.84 | HCAR3 (0.74) | HCAR3CDC25BHTTALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL321637 | 0.84 | HCAR3 (0.97) | HCAR3CDC25BMEN1KMT2A | |
| SCHEMBL1602521 | 0.83 | HCAR3 (0.76) | HCAR3HTTALDH1A1MAPTMEN1 | |
| SCHEMBL1726941 | 0.83 | HCAR3 (0.72) | HCAR3CDC25BHTTALDH1A1MAPT | |
| SCHEMBL9190453 | 0.81 | HCAR3 (0.70) | HCAR3CDC25BHTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116178203-B | Polyimide containing amide bond and benzonorbornane structure and preparation method thereof | 南昌大学 | 2025-02-14 | — | — | CN | claimed |
| CN-117510402-A | Optimized dabigatran etexilate key intermediate synthesis process | 江苏阿尔法药业股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-116178203-A | Polyimide containing amide bond and benzonorbornane structure and preparation method thereof | 南昌大学 | 2023-05-30 | — | — | CN | claimed |
| CN-112960764-B | Landfill leachate denitrification method | 杭州楠大环保科技有限公司 | 2022-05-24 | — | — | CN | claimed |
| CN-112960764-A | Landfill leachate denitrification method | 杭州楠大环保科技有限公司 | 2021-06-15 | — | — | CN | claimed |
| CN-103524559-B | Ester derivant of polysubstituted 4-methylamino benzenecarboximidamide and its production and use | 西藏海思科药业集团股份有限公司 | 2016-09-28 | — | — | CN | claimed |
| CN-104356022-B | A kind of synthetic method of N-methyl-4-(methylamino)-3-nitrobenzamide | 上海应用技术学院 | 2016-06-08 | — | — | CN | claimed |
| CN-104356022-A | Synthetic method of N-methyl-4-(methyl amino)-3-nitrobenzamide | SHANGHAI INST TECHNOLOGY | 2015-02-18 | — | — | CN | claimed |
| CN-104230888-A | Preparation method of benzimidazole compound | UNIV CHANGCHUN TECHNOLOGY | 2014-12-24 | — | — | CN | claimed |
| CN-103694224-A | Dabigatran etexilate analog centered by fluorine-containing-group-modified benzene ring and synthesis method thereof | SHANGHAI INST TECHNOLOGY | 2014-04-02 | — | — | CN | claimed |
| CN-103524559-A | Ester derivatives of multi-substituted 4-methylamino-benzamidine as well as preparation method and application of ester derivatives | TIBET HAISCO PHARMACEUTICAL GROUP CO LTD | 2014-01-22 | — | — | CN | claimed |
| US-8394961-B2 | Method for the preparation of dabigatran | ZENTIVA K.S. (CZ) | 2013-03-12 | — | — | US | claimed |
| US-20110082299-A1 | METHOD FOR THE PREPARATION OF DABIGATRAN | ZENTIVA K.S. (CZ) | 2011-04-07 | — | — | US | claimed |
| EP-2262771-A1 | A METHOD FOR THE PREPARATION OF DABIGATRAN | Zentiva, K.S. (CZ) | 2010-12-22 | — | — | EP | claimed |
| WO-2009111997-A1 | A METHOD FOR THE PREPARATION OF DABIGATRAN | ZENTIVA, K.S. (CZ) | 2009-09-17 | — | — | WO | claimed |
| CN-116178203-B | Polyimide containing amide bond and benzonorbornane structure and preparation method thereof | 南昌大学 | 2025-02-14 | — | — | CN | disclosed |
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2024-09-17 | — | — | US | disclosed |
| US-6414008-B1 | CYNAO- OR AMIDINE-SUBSTITUTED BENZIMIDAZOLES, BENOTHIAZOLES, OR BENZOXAZOLES; 2-(N-(4-AMIDINOPHENYL)AMINOMETHYL)BENZOTHIAZOLES; 2-((4-CYANOPHENYL)OXYMETHYL)IMIDAZOL(4,5-B)PYRIDINES; ANTITHROMBOTICS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-07-02 | — | — | US | disclosed |
| US-6087380-A | ANTITHROMBOTIC BENZIMIDAZOLES; ANTICOAGULANTS; 2-(N-(4-AMIDINOPHENYL)-AMINOMETHYL)-BENZIMIDAZOL-5-YL-CARBOXYLIC ACIDS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-07-11 | — | — | US | disclosed |
| CN-1248251-A | Disubstituted bicyclic heterocycles, their production and use as medicaments | BOEHRINGER INGELHEIM PHARMA (DE) | 2000-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | HCAR3 1803/4885CDC25B 4293/4885HTT 1101/4885 |
| US-20110082299-A1 | METHOD FOR THE PREPARATION OF DABIGATRAN | PROC, VKORC1, VKORC1L1 | HCAR3 660/4885CDC25B 1993/4885HTT 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.